Neurology
QurAlis receives authorisation to initiate ALS therapy trial in EU
ANQUR is said to be the first-ever study to evaluate a therapy that rescues STATHMIN-2 expression in patients with ALS.
Alzinova doses first patient in extension part of Phase Ib ALZ-101 trial
Alterity initiates new Phase II advanced MSA therapy trial
Larimar reports results from Friedreich’s ataxia drug trial
Argenica Therapeutics receives Phase I trial report for ARG-007
Newron reports additional data from study 014/015 of TRS therapy
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
